Trump pauses funding for anti-HIV program that prevented 26 million AIDS deaths; NPR, January 27, 2025

Melody Schreiber, NPR; Trump pauses funding for anti-HIV program that prevented 26 million AIDS deaths

[Kip Currier: The amorality of the statement below is staggeringly appalling, but not unexpected, from an administration whose guiding principle is transactional policymaking, even in examples involving great human suffering and need.

To label as "a moral imperative" the immediate cessation of lifesaving medications for Global South persons with HIV and AIDS is farcical Orwellian rhetoric.]

[Excerpt]

"On Sunday, the State Department confirmed the halt in an email to NPR. The United States "is no longer going to blindly dole out money with no return for the American people," State spokesperson Tammy Bruce said in a statement, calling the pause "a moral imperative.""

Trump Administration Halts H.I.V. Drug Distribution in Poor Countries; The New York Times, January 27, 2025

 Apoorva Mandavilli, The New York Times; Trump Administration Halts H.I.V. Drug Distribution in Poor Countries

"The Trump administration has instructed organizations in other countries to stop disbursing H.I.V. medications purchased with U.S. aid, even if the drugs have already been obtained and are sitting in local clinics.

The directive is part of a broader freeze on foreign aid initiated last week. It includes the President’s Emergency Plan for AIDS Relief, the global health program started by George W. Bush that is credited with saving more than 25 million lives worldwide.

The administration had already moved to stop PEPFAR funding from moving to clinics, hospitals and other organizations in low-income countries.

Appointments are being canceled, and patients are being turned away from clinics, according to people with knowledge of the situation who feared retribution if they spoke publicly. Many people with H.I.V. are facing abrupt interruptions to their treatment...

“The partners we collaborate with are in shock, and they do not know what to do because their lifesaving mission and commitment has been breached,” said Asia Russell, executive director of the advocacy group Health Gap."

Act now on AI before it’s too late, says UNESCO’s AI lead; Fast Company, February 6, 2024

CHRIS STOKEL-WALKER, Fast Company; Act now on AI before it’s too late, says UNESCO’s AI lead

"Starting today, delegates are gathering in Slovenia at the second Global Forum on the Ethics of AI, organized by UNESCO, the United Nations’ educational, scientific, and cultural arm. The meeting is aimed at broadening the conversation around AI risks and the need to consider AI’s impacts beyond those discussed by first-world countries and business leaders.

Ahead of the conference, Gabriela Ramos, assistant director-general for social and human sciences at UNESCO, spoke with Fast Company...

Countries want to learn from each other. Ethics have become very important. Now there’s not a single conversation I go to that is not at some point referring to ethics—which was not the case one year ago...

Tech companies have previously said they can regulate themselves. Do you think they can with AI?

Let me just ask you something: Which sector has been regulating itself in life? Give me a break."

As pandemic raged, global south lacked vaccines. Never again, researchers vow.; The Washington Post, July 16, 2023

Amy Maxmen , The Washington Post; As pandemic raged, global south lacked vaccines. Never again, researchers vow.

"Once it became clear that wealthy nations would help themselves to coronavirus vaccines long before poorer nations had access, researchers across Africa, Asia and South America banded together with the World Health Organization. Never again, they vowed, would they allow themselves to be at the mercy of the Western world while a deadly pathogen tore through their regions...

Called the mRNA vaccine technology transfer hub, a mouthful meant to reflect their intention to share mRNA technology, the initiative is distinct from the typical, competitive mode of drug development in which companies keep discoveries secret."